{
    "clinical_study": {
        "@rank": "19815", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: iv danoprevir", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 1: placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Part 2 A: iv danoprevir", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 2 B: oral danoprevir", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Part 2 C: ritonavir", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Part 3 D: iv danoprevir", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 3 E: iv danoprevir + cyclosporine", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This three-part study will evaluate the pharmacokinetics and bioavailability of intravenous\n      danoprevir with and without low-dose oral ritonavir, and the effect of oral cyclosporine on\n      the pharmacokinetics of intravenous danoprevir with ritonavir in healthy volunteers."
        }, 
        "brief_title": "A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult healthy male and female nonsmoking volunteers, 18 to 55 years of age inclusive;\n             healthy status will be defined by absence of evidence of any active or chronic\n             disease following a detailed medical and surgical history and a complete physical\n             examination\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women or males with female partners who are pregnant or\n             lactating\n\n          -  Positive results for drugs of abuse at screening or prior to admission to the\n             clinical site during any study period\n\n          -  Positive for hepatitis B, hepatitis C or HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654211", 
            "org_study_id": "NP28297", 
            "secondary_id": "2012-000470-40"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1: iv danoprevir", 
                    "Part 2 A: iv danoprevir", 
                    "Part 3 D: iv danoprevir", 
                    "Part 3 E: iv danoprevir + cyclosporine"
                ], 
                "description": "single iv infusion", 
                "intervention_name": "danoprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2 B: oral danoprevir", 
                "description": "single oral dose", 
                "intervention_name": "danoprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: iv danoprevir", 
                    "Part 1: placebo", 
                    "Part 2 A: iv danoprevir", 
                    "Part 2 B: oral danoprevir", 
                    "Part 2 C: ritonavir", 
                    "Part 3 D: iv danoprevir", 
                    "Part 3 E: iv danoprevir + cyclosporine"
                ], 
                "description": "oral doses", 
                "intervention_name": "ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 1: placebo", 
                "description": "single iv infusion", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Ritonavir", 
                "Lactams"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471 GP"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Three-Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low-Dose Ritonavir (RTV), the Absolute Bioavailability of DNV With and Without Oral Low-Dose RTV, and the Effect of Oral Cyclosporine on IV DNV/Oral Low-Dose RTV in Healthy Adult Volunteers", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 12 hours post-dose"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 7 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654211"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}